Introduction
============

Obesity has become a critical worldwide health concern in the past few decades, as the worldwide prevalence of obesity has more than doubled over the past 35 years. The World Health Organization estimated there were more than 1.9 billion overweight adults 18 years and older in the year 2014. Of these, over 600 million were obese.[@b1-cia-11-367] Obesity is a major risk factor for multiple health problems, including type 2 diabetes,[@b2-cia-11-367] coronary heart disease,[@b3-cia-11-367] sleep apnea,[@b4-cia-11-367] osteoarthritis,[@b5-cia-11-367] and certain forms of cancer,[@b6-cia-11-367]--[@b8-cia-11-367] as well as increased risk of death from such diseases.[@b9-cia-11-367] Weight loss can help reduce blood pressure and blood cholesterol, and improve glucose tolerance in people prone to diabetes.[@b10-cia-11-367]

Although robust weight loss may be ideal for obese people, even a modest reduction in weight can have clinically meaningful and significant health benefits. For the management of obesity, behavior-based (diet and lifestyle) treatment programs have been shown to improve weight-loss results as the most commonly used treatment.[@b11-cia-11-367] Beverages, such as teas brewed from the leaves of *Camellia sinensis*, are easily incorporated into a daily routine. Various types of tea are categorized based on the degree of fermentation during manufacturing, each of the four types with different chemical composition and health benefits: nonfermented (green) tea, partially fermented (oolong) tea, fully fermented (black) tea, and postfermented tea (Puer).[@b12-cia-11-367]--[@b15-cia-11-367]

Puer tea originated in Yunnan Province in imperial China, and has long been consumed as one of the most popular beverages in Asia.[@b16-cia-11-367] Historically, Puer tea was used as a medicinal drink in the treatment of a variety of illnesses, such as common colds, flatulence, poor digestion, and onset of dysentery.[@b17-cia-11-367] In the past few decades, the unique effects of Puer tea have been extensively studied, and results indicate that Puer tea possesses a broad range of health-promoting effects, including hypoglycemic effects[@b18-cia-11-367],[@b19-cia-11-367] and improvement of type II diabetes, as well as inhibition of the progression of diabetic complications.[@b20-cia-11-367]

Of pertinence to the study reported here, studies in rodents have shown that consumption of Puer tea can decrease weight gain[@b21-cia-11-367],[@b22-cia-11-367] and improve hyperlipidemia conditions.[@b23-cia-11-367]--[@b25-cia-11-367] The beneficial properties of Puer tea may in part be attributable to the bioactive components theabrownin,[@b26-cia-11-367] theaflavins,[@b12-cia-11-367] and complex polysaccharides.[@b27-cia-11-367] The statin compound lovastatin has been identified in Puer tea,[@b28-cia-11-367] and lovastatin levels increase with fermentation of tea leaves.[@b29-cia-11-367],[@b30-cia-11-367] However, the levels of statins that can be found in some sources of Puer tea are several hundredfold lower than a low dose of statin delivered as a drug for hyperlipidemia,[@b29-cia-11-367],[@b31-cia-11-367] and thus quite unlikely to contribute significantly to the overall effects of Puer tea consumption.

Despite the large volume of studies of Puer tea in rodents, only a few clinical studies have been conducted to investigate the health-promoting effect of Puer tea in humans. A 3-month double-blind randomized study was performed in borderline hypercholesterolemic human subjects in a Japanese population. The result showed significant improvements in lipid profile.[@b32-cia-11-367] The antiobesity effect of Puer tea was documented in overweight Japanese adults (body mass index \[BMI\] 25--30 kg/m^2^), where intake of Puer tea was associated with reduction of body weight, mean waist circumference, BMI, and visceral fat.[@b33-cia-11-367] Previous publications on human clinical trials documenting the effects of Puer tea were conducted in populations of Asian ethnicity, diet, and lifestyle. The study reported here aimed at evaluating changes in weight, fat mass, and lipid profile in hyperlipidemic subjects in a North American population.

Materials and methods
=====================

Study design
------------

A randomized, double-blind, placebo-controlled study design was used for this clinical study, with a duration of 20 weeks and visits every 4 weeks. A total of 59 overweight or mildly obese adult men and women were enrolled in the study after screening for cholesterol level at 220 mg/dL or higher and signing written informed consent. This study was approved by the ethical committee of Sky Lakes Medical Center. The study population comprised of 58 Caucasians and one Hispanic. An even sex distribution was not a criteria for the study, and a female:male ratio of 2:1 reflected the higher interest and availability of women to participate in this type of clinical trial. Inclusion criteria were 35--75 years of age, BMI 25--35 kg/m^2^; waist circumference higher than 80 cm for women and higher than 96 cm for men, and fasting cholesterol level of 220 mg/dL or higher. Exclusion criteria were: treated with statin hyperlipidemia medication for the past month; treated with other medication specifically for hyperlipidemia; daily alcohol use of four or more standard units/day (or 28 or more per week); screening blood results of complete blood count and liver and renal function judged to be of clinical significance; currently treated with insulin (other forms of diabetic medication were allowed); pregnancy (a pregnancy test was provided at screening for pre- and perimenopausal women); unwilling to maintain a constant regimen of medication and supplements for the duration of the study (based on their habitual consumption during the past 2 months prior to entering this study), with the exception of changes to medication needed for the optimal care of each person; blood donation during the 2 weeks prior to study start; participation in other clinical trials during the last month; and food allergies or sensitivities related to the test product.

Consumables
-----------

The Puer tea and placebo powders were prepared in a serving-size sachet, boxed, and labeled with instructions at Tasly Pharmaceuticals Inc. The placebo powder was prepared from dextrin produced from cornstarch. Packages of a 4-week (56 servings for 28 days) supply were prepared. Subjects were randomized to receive either placebo or Puer tea for the duration of the study. At the baseline visit and visits at 4, 8, 12, and 16 weeks, subjects were provided with a 4-week supply of their assigned consumable. Subjects were instructed to consume two 1.5 g portions daily with meals, with instructions to dissolve the content of one sachet in approximately one cup warm water (250 mL) immediately before consuming. Subjects were allowed to add a small amount of milk and/or sugar. Adherence to the study protocol was evaluated at each visit by documentation of the returned product, an interview with the study coordinator, and review of the diary.

Blood pressure measurements
---------------------------

Blood pressure was recorded at each visit using an Omron BP 742 monitor, after the subject had sat quietly for 3 minutes.

Blood testing
-------------

Blood was drawn using venipuncture at each visit and tested for lipid profile, C-reactive protein (CRP), and fasting blood glucose.

Body measurements
-----------------

Body height was measured at the study start. Weight measurements were performed at each visit using a mechanical scale. A fabric tape was used to perform measurements of the waist, hip, thigh, and upper arms. The waist measurement was performed at the smallest area of the trunk for women, and at the navel line for women without an apparent waist. The waist measurement for men was always taken at the navel line. Subjects were instructed to relax and not flex the abdominal muscles during the waist measurement. Upper-arm measurements were performed on the dominant side of the body, with the arm held outstretched and parallel to the floor while the largest point above the elbow was measured. Hip measurements were performed around the largest circumference of the body below the waist and above the thigh. Thigh measurements were performed on the dominant side of the body, at the largest point above the knee, with the subject standing with the legs a shoulder width apart.

Dual energy X-ray absorptiometry
--------------------------------

Body-fat composition was performed by whole-body dual-energy X-ray absorptiometry (DEXA) scanning, using a Lunar DEXA scanner (Prodigy series X-ray; GE Healthcare, Little Chalfont, UK). A quality-assurance calibration scan was performed once a day prior to scanning the subjects. Subjects were positioned in the center of the table with their arms separated from the sides of the body and their hands placed with the palms against their thighs and the elbows tucked into their sides. Their knees and ankles were strapped into place. Their head was adjusted so the midline of the table was aligned with the middle of the head, and the subject's legs were adjusted so the midline of the table was between the legs. The scan lasted 6--11 minutes, depending on the size of the volunteer. If the volunteer moved during the scan, the scan was aborted, the person was then repositioned, and the scan was restarted. The resulting data from the DEXA scan were analyzed using Encore 2011 software, where regional analysis includes lean and fat mass for arms, legs, trunk, android (belt area), gynoid (hip area), and total body.

Questionnaire-based data collection
-----------------------------------

At each visit, questions pertaining to appetite and satiety were scored using unmarked visual analog scales.

Statistical analysis
--------------------

Average and standard deviation for each data set were calculated using Microsoft Excel. Statistical analysis of clinical data was performed as between-group comparison of the group averages for each time point in the study using the two-tailed, unpaired *t*-test. The statistical significance of changes from baseline to later assessments was evaluated by between-treatment analysis using within-subject analysis and the two-tailed paired *t*-test. Statistical significance was indicated by *P*\<0.05, and a high level of significance was indicated by *P*\<0.01.

Results
=======

Study enrollment, compliance, and completion
--------------------------------------------

In order to complete the enrollment for this study, a total of 171 people were screened, and 112 failed screening: 85 failed due to cholesterol below 220 mg/dL, one was excluded because of extremely high triglycerides (over 500 mg/dL), eight were excluded because of their BMI, and the remaining subjects failed screening for other reasons.

Of the 59 people enrolled, 49 completed the 20-week participation ([Figure 1](#f1-cia-11-367){ref-type="fig"}). Four people in the placebo group and one in the Puer tea extract (PTE) group discontinued study participation for various medical reasons, including change in medication and health status. An additional five people discontinued participation at various times during the 20-week study, due to practical issues (moving, traveling) or loss of interest. One female subject who completed the study was removed from analysis due to noncompliance in terms of maintaining a constant diet and lifestyle during the study, which was manifested by a substantial weight gain (29% increase in body weight during the study, compared to her body weight at baseline).

There were no statistically significant differences between age, BMI, or physical measurements between the subjects randomized to placebo versus PTE for either the female or male subject group ([Table 1](#t1-cia-11-367){ref-type="table"}).

Body mass index, body measurements, and body-fat composition
------------------------------------------------------------

A statistically significant reduction in BMI was seen at 20 weeks for the PTE group when compared to the placebo group (*P*\<0.05) ([Figure 2](#f2-cia-11-367){ref-type="fig"}). The average reduction in body weight in the PTE group was small (1 kg), but highly significant (*P*\<0.01).

Body measurements showed a decrease in hip and waist measurements in the PTE group, but the changes did not reach statistical significance (data not shown). Body measurements showed an increase in thigh circumference at study exit for the subjects in the PTE group, which associated with the fat loss for the same region suggested an increase in muscle mass for that region.

The weight loss corresponded to a reduction in total body fat at 20 weeks for the PTE group when compared to the placebo group ([Figure 3A](#f3-cia-11-367){ref-type="fig"}). This change was not statistically significant between the two groups, but the change was significant within the PTE group (*P*\<0.05).

The loss of body fat was seen in the trunk, arm, and leg regions ([Figure 3B--D](#f3-cia-11-367){ref-type="fig"}). Regional analysis of trunk fat showed that the fat loss was less obvious for the android region ([Figure 3E](#f3-cia-11-367){ref-type="fig"}), but was predominant for the gynoid (hip) region ([Figure 3F](#f3-cia-11-367){ref-type="fig"}). There was no statistical difference in gynoid fat between the groups at study exit, but when the data within the PTE group were analyzed, the fat loss in the gynoid region was statistically significant (*P*\<0.05). There were no significant differences in lean or bone mass between the two groups (data not shown).

Self-reported appetite showed a high degree of consistency in the PTE group, whereas the placebo group showed variations across the 20 weeks. Lower appetite was seen for weeks 4--16 in the PTE group when compared to placebo, reaching a statistical trend at week 8 (*P*\<0.1). No other significant differences were seen.

Lipid profile
-------------

There was no significant difference in the cholesterol levels between the two groups at any time during the study ([Figure 4A](#f4-cia-11-367){ref-type="fig"}). However, within the PTE group, data showed that consumption of PTE was associated with a significant reduction in cholesterol levels, starting at week 4 and remaining significantly lower than baseline throughout the study. In contrast, the changes within the placebo group showed only a transient lowering of cholesterol levels at weeks 4 and 8, likely due to a transient increase in awareness of diet and lifestyle in the early phase of study participation, and returning almost to baseline levels at weeks 12, 16, and 20.

There was no significant difference in high-density lipoprotein (HDL) levels between the two groups at any time during the study ([Figure 4B](#f4-cia-11-367){ref-type="fig"}). Under within-group analysis, consumption of placebo was associated with a statistical trend for lower HDL levels at week 8.

There was no significant difference in cholesterol:HDL levels between the two groups at any time during the study (data not shown). However, under within-group analysis, consumption of PTE was associated with statistical trends for lowering the cholesterol:HDL levels at weeks 4 and 20, and with statistical significance at week 16.

Low-density lipoprotein levels were not significantly affected by PTE consumption in this study population ([Figure 4C](#f4-cia-11-367){ref-type="fig"}). A transient reduction in low-density lipoprotein levels was seen in both the PTE and placebo groups, suggesting that the awareness of being in a weight-management study with a focus on cholesterol/weight management may have affected fat intake.

When compared to the placebo group at week 20, reduced triglyceride levels in the PTE group showed a trend (*P*\<0.1) ([Figure 4D](#f4-cia-11-367){ref-type="fig"}). The average percentage change showed a trend for reduced triglyceride levels in the PTE group when compared to the placebo group at week 8. Under within-group analysis, consumption of PTE was associated with a significant reduction in triglyceride levels at week 8 and continued to decrease throughout the 20-week study, with the exception of a mild transient increase at week 12. A transient increase in triglyceride levels was seen in both groups at week 12; this transient increase reached a statistical trend for the placebo group, but was not significant in the PTE group.

Blood pressure
--------------

There was no change in blood pressure in either group, despite the content of stimulants in PTE. There were no statistically significant differences between average systolic or diastolic blood pressure at baseline or during the study in either the female or male subpopulation ([Table 2](#t2-cia-11-367){ref-type="table"}).

C-reactive protein
------------------

Blood samples were tested for CRP levels at each visit. At baseline, the average CRP level in the PTE group was 0.25±0.04 mg/dL, and in the placebo group was 0.22±0.04 mg/dL. Over the course of the 20-week study, average high-sensitivity CRP levels remained well within the normal range (below 3.0 mg/dL), and the group averages for each time point were similar for both product and placebo across the 20-week study.

Fasting blood glucose
---------------------

Subjects were examined for fasting blood glucose levels at each visit ([Figure 5](#f5-cia-11-367){ref-type="fig"}). There was no significant change in fasting glucose over the course of the 20-week study. However, from week 8 and onward, the fasting blood glucose levels for the PTE group remained below the levels seen in the placebo group. This was seen for both sexes.

Discussion
==========

Preserving good metabolic and cardiovascular health is important, and is related to many dietary and lifestyle factors, including maintenance of healthy body weight and healthy levels of blood lipids. Obesity is a critical worldwide health concern, a major risk factor for many high-profile chronic diseases, and is of increasing global concern and impact on health-service systems. Lifestyle options, such as the daily consumption of health-promoting beverages, are practical tools to help sustain a healthy cardiovascular system, with personal and societal benefits.

Tea consumption represents a simple choice to substitute for other beverages on a daily basis, and is associated with decreased mortality, as well as specific decrease in mortality from cardiovascular and cancerous illnesses.[@b34-cia-11-367] Tea polyphenols have neuroprotective effects beyond their antioxidant properties, and it has been suggested that tea consumption should be considered a lifestyle choice in the prevention of neurodegenerative disorders.[@b35-cia-11-367] The different content of tea polyphenols in various types of tea is associated with different biological effects, and specifically Puer tea has been associated with downregulation of enzymes involved in fat storage.[@b36-cia-11-367]

Previous clinical studies on Puer tea have been performed in Asia, where the genetic predisposition to obesity and hyperlipidemia, as well as diet and lifestyle, are distinctly different from Western regions, including Europe and North America. The data reported here are to the best of our knowledge the result of the first controlled trial on Puer tea performed outside Asia.

In line with previously published evidence, we observed a reduction in body fat in the group consuming PTE. It is important to note that the fat loss and improved blood lipids happened with no diet restrictions. Regional analysis of the DEXA data showed that the fat loss was seen for multiple regions, including the arms, legs, trunk, and the gynoid region. This is particularly interesting, since abdominal fat is associated with increased cardiovascular risk.

Lipoproteins are important and necessary for the transport of lipid nutrients and hormones in the bloodstream. However, elevated levels are associated with increased cardiovascular risk. Previous studies in animals that were fed a high-fat diet showed that Puer tea consumption helped maintain healthy cholesterol levels.[@b12-cia-11-367],[@b25-cia-11-367]--[@b30-cia-11-367] Two previous clinical trials were performed in Asia, and confirmed reduced cholesterol in people consuming Puer tea.[@b32-cia-11-367],[@b33-cia-11-367] The aqueous extract of Puer tea has been shown to have specific effects on enzymes involved in lipid metabolism, and acts as a competitive inhibitor for HMGCR and pancreatic lipase and as a noncompetitive inhibitor for Lp-PLA~2~.[@b37-cia-11-367] In the study reported here, we observed only minor changes to cholesterol and HDLs. In contrast, we saw clinically important reduction in triglycerides. Both the PTE and placebo groups had baseline levels well above 150 mg/dL, but the PTE group showed a reduction within 8 weeks, where the group average was within the normal range at 8 weeks and remained within the normal range throughout the remainder of the 20-week study. This suggests that PTE may help cardiovascular health, particularly in the hypertriglyceridemic waist phenotype, which is one of the most predictive of a cardiovascular disease risk.[@b38-cia-11-367]--[@b41-cia-11-367]

Despite previous evidence from a rodent study that Puer tea consumption helps manage blood glucose,[@b27-cia-11-367] we did not see a change in fasting blood glucose in the study reported here. The data from this study suggest that daily consumption of PTE supports improved cardiovascular health in several ways, including weight management through loss of body fat and beneficial changes to blood lipids, specifically with respect to reduced triglycerides and very low-density lipoprotein. One limitation of the study reported here is that it was conducted in a hyperlipidemic population but not hyperglycemic. It is highly recommended that further studies be performed. These should aim at documenting reduction of body fat in people who are not hyperlipidemic, and should also examine the effects of consuming Puer tea in conjunction with a weight-loss program, improved glucose tolerance, and overall metabolic health through regulation of adipokines.

This study was conducted at NIS Labs, an independent contract research laboratory specializing in natural-product research. The study was sponsored by Tasly Pharmaceuticals USA.

**Disclosure**

GSJ and JLB are employees of NIS Labs, an independent contract research organization specializing in natural-product research, and have no competing financial interest in the subject matter. YH, ZXG, and HS are employees of Tasly Pharmaceuticals, the sponsor of this study.

![Consort flowchart.\
**Note:** Chart shows screening and randomization, as well as the number of people completing each 4-week phase of the 20-week study on Puer tea extract.](cia-11-367Fig1){#f1-cia-11-367}

![Body mass index (BMI).\
**Notes:** Shown as the group averages ± standard error of mean for the Puer tea extract (PTE) group (solid lines) and the placebo group (dashed lines). There was a significant difference in BMI between the two groups at week 20. The BMI reduction within the PTE group over the course of the 20-week study was highly significant. ^\*^*P*\<0.05, ^\#\#^*P*\<0.01.](cia-11-367Fig2){#f2-cia-11-367}

![Changes in total body fat and regional fat composition.\
**Notes:** Shown as the group averages of the individual percentage changes ± standard error of mean for the Puer tea extract (PTE) group (solid lines) and the placebo group (dashed lines). There were no significant differences between the two groups at week 20; however, the between-group difference in fat loss in the arms showed a statistical trend. Within the group consuming PTE, a significant loss of total body fat was seen. The total fat loss was associated with regional fat loss in the trunk, arms, thighs, and gynoid (belly/hip) regions. The fat loss in the gynoid region within the PTE group was statistically significant. ^\*^*P*\<0.1, ^\#^*P*\<0.05.](cia-11-367Fig3){#f3-cia-11-367}

![Lipid data are shown as group averages ± standard error of mean for the Puer tea extract (PTE) group (solid lines) and the placebo group (dashed lines).\
**Notes:** There were no significant differences between the PTE and placebo results for cholesterol (**A**), HDL (**B**), or LDL (**C**). Within the PTE group, a significant reduction in cholesterol levels was seen already at week 4, and remained statistically significantly lower than baseline throughout the study. Triglyceride levels showed a reduction in the PTE group that was not statistically significant, but was clinically important (**D**): the group average in the PTE group went down into the normal range (below 150 mg/dL) after 8 weeks, and remained low throughout the remainder of the study. After 20 weeks, there was a 20% reduction in the average triglyceride levels within the PTE group (*P*\<0.08).\
**Abbreviations:** HDL, high-density lipoprotein; LDL, low-density lipoprotein.](cia-11-367Fig4){#f4-cia-11-367}

![Fasting blood glucose levels.\
**Notes:** Shown as group averages ± standard error of mean for the Puer tea extract (PTE) group (solid lines) and the placebo group (dashed lines). There were no significant differences between the PTE and placebo results during the study; however, the fasting blood glucose levels remained lower in the PTE group than the placebo group from week 8 throughout the remainder of the 20-week study.](cia-11-367Fig5){#f5-cia-11-367}

###### 

Characteristics of study population

                       Placebo       Puer tea extract   *P*-value[\*](#tfn1-cia-11-367){ref-type="table-fn"}
  -------------------- ------------- ------------------ ------------------------------------------------------
  **Females**          19            20                 
  Average age, years   55±10         57±9               0.589
  Age range, years     38.1−70.1     38.7−72.3          
  BMI average          30.7±4.5      29.3±3.2           0.257
  BMI range            25.2−40       25.1−35.2          
  Height average, cm   163±6         163±5              0.990
  Height range, cm     147.3−171.5   153.7−172.7        
  Weight average, kg   82±15         78±10              0.339
  Weight range, kg     59.1−114.1    65.9−98.2          
  **Males**            10            10                 
  Average age, years   55±11         52±8               0.616
  Age range, years     42−73.4       39.2−65.9          
  BMI average          29±3          31±4               0.269
  BMI range            25.8−36.7     26.4−39.5          
  Height average, cm   177±7         177±7              0.935
  Height range, cm     169.5−190.5   160−184.8          
  Weight average, kg   92±12         98±15              0.369
  Weight range, kg     76.8−113.6    76.1−126.8         

**Notes:**

There were no statistically significant differences between age and physical measurements between the subjects randomized to placebo versus Puer tea for either female or male subject group. Data presented as n or mean ± standard deviation.

**Abbreviation:** BMI, body mass index.

###### 

Systolic and diastolic blood pressure during the study

                Placebo   Puer tea extract   *P*-value                    
  ------------- --------- ------------------ ----------- -------- ------- -------
  **Females**                                                             
  Baseline      129±4.7   82±2.3             120±2.8     75±1.9   0.110   0.018
  4 weeks       130±5.2   80±2.0             119±2.8     75±1.9   0.080   0.055
  8 weeks       123±3.8   80±1.6             118±3.0     76±1.8   0.291   0.086
  12 weeks      128±3.3   82±2.3             123±3.2     76±1.9   0.245   0.027
  16 weeks      129±5.0   82±2.7             122±5.1     74±2.2   0.330   0.028
  20 weeks      125±4.2   81±2.1             121±3.7     76±1.9   0.404   0.072
  **Males**                                                               
  Baseline      134±4.9   84±2.0             128±4.2     82±1.5   0.334   0.308
  4 weeks       137±6.0   85±2.1             131±6.9     81±2.7   0.472   0.304
  8 weeks       143±8.1   83±3.9             135±7.9     84±3.0   0.506   0.842
  12 weeks      138±9.0   86±2.8             132±5.9     82±2.0   0.598   0.280
  16 weeks      132±7.2   85±2.3             134±8.8     83±2.1   0.880   0.544
  20 weeks      134±6.2   87±3.2             125±3.3     81±1.2   0.212   0.121

**Notes:** Data presented as mean ± standard deviation unless otherwise stated.
